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Summary: Multivariate analysis confirmed that HLA-DRB1 
matching was the most significant factor influencing 
survival (P = 0.04), LFS (P = 0.013) and TRM 
(P = 0.0049). From these results, we have defined a 
‘good risk’ group, ie patients transplanted in first 
chronic phase, from an HLA-DUB 1 matched donor, 
without TCD as prophylaxis against GVHD. The 2 year 
LFS, TRM and relapse incidence for this group were 
51 ±5% , 47 ±5% and 2 ±2%, respectively. This sug- 
chronic phase and 116 in advanced phases. The median gests that the long-term outcome of patients with favor- 
interval from diagnosis to BMT was 827 days. GVHD able prognostic features can approach that of patients
We have retrospectively analyzed the impact of prog­
nostic factors on the outcome of serologically HLA- 
matched unrelated donor (UD) BMT for CML. For this 
purpose, we have studied a cohort of 366 patients trans­
planted in Europe between January 1985 and December 
1994. The median age of the 211 males and 155 females 
was 34 years; 238 patients were transplanted in first
prophylaxis consisted of CsA and MTX in 202 patients 
or of ex vivo or in vivo T cell depletion (TCD) in 129.
transplanted from geno-identical siblings. In contrast, 
the TRM for patients transplanted for advanced disease
Recently, DNA-based methods of HLA-class II typing from non HLA-DRB1-identical donors was 94%. Such 
have been used to improve donor selection. We obtained a high TRM clearly indicates that UD BMT is not
complete data on 300 donor/recipient (D/R)
Among them, we have three groups
patients, according to specific HLA-DRB1 D/R compati­
bility. Two hundred and ten patients received marrow 
from donors identical for HLA-DRB1 (group 1). Thirty- 
one patients received BMT from a donor who was HLA- 
DRB1 mismatched (group 2) and 59 from a donor in 
whom specific HLA-DRB1 typing was not performed 
(group 3). The overall survival was 37 ± 3% at 2 years 
and leukemia-free survival (LFS) was 31 ±3%.  In univ­
ariate analysis, five variables had a favorable effect on 
LFS: transplant in first chronic phase (P = 0.0001), time 
Interval from diagnosis to BMT shorter than the median 
( /> = 0.01), prophylaxis of GVHD without TCD 
(P = 0.001), acute GVHD <grade III (ƒ> = 0.0009) and 
HLA-DRB1 D/R matching (P -  0.0001 ). Transplant-
justifiable for these individuals. 
Keywords: chronic myeloid 
bone marrow transplant
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For patients with CML, allogeneic BMT from an HLA- 
identical sibling is the treatment of choice.1 ''
most patients do not have a suitable sibling donor and, for 
these individuals, there are a number of treatment options.
st are now tret a-IFN, as this therapy can 
induce a major or a complete cytogenetic response in some 
patients“1 and improve the median survival, compared to
tret
related mortality was 49 ±4% in 1 ,
with hydroxyurea alone.0,7 
fewer than 50% of patients have a useful 
response and blast transformation is observed even in those 
patients who have responded. Finally, there is no evidence,
7 9  ± 8% in group 2 and 80 ±6%  in group 3 (P = 0.0001). as yet, that this treatment can cure any patient. Similarly,
s tn antation may
vival in some patients,8 but is also unlikely to result in cure.
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method of GVHD prophylaxis, and a tendency to delay the 
transplant so that the interval from diagnosis to BMT is 
greater than that in an equivalent cohort of sibling trans­
plant patients. Furthermore, there is an increased incidence 
of acute and chronic G V H D  and an increased incidence of 
life-threatening viral infections, both o f  which might reflect 
the degree of HLA disparity.9' 13 Selection of suitable unre­
lated donors has previously relied upon serological identi­
fication of HLA-A, -B and -DR alleles. Sequencing of the 
HLA genes has now  revealed a far greater degree of poly­
morphism at these loci than that detected by serology.14 As 
a consequence, many unrelated serologically matched pairs 
have subsequently been shown to have undisclosed mis­
matches. In order to analyze the impact of improved resol­
ution of class II typing on U D  BMT outcome, we have 
conducted a retrospective analysis of 366 patients reported 
to the chronic leukem ia registry o f the European Group for
Table I Clinical details o f 366 patients
Blood and M
CM L
Transplantation (EBMT)
based typing of H L A -D R B 1 was available for the majority 
of patients allowing us to analyze the effects of accurate 
matching on transplant outcome.
Patients and methods
Patients
The registry o f the chronic leukemia working party 
(CLWP) of the EBM T contains data on 374 patients who 
were transplanted for CM L from donors matched serologi­
cally for HLA-A, H LA -B and HLA-DR. Three hundred and 
sixty-six of these patients are evaluable for analysis of sur­
vival, leukemia-free survival (LFS), transplant-related mor­
tality (TRM) and relapse incidence (RI). The patients were 
transplanted between January 1985 and December 1994. 
Analysis was conducted after February 1995, giving a 
median follow-up o f  32 months (range 2-110 months). 
Patient details are provided in Table 1.
g regimen
Of the 366 patients, 322 (88%) received TBI and chemo­
therapy. The irradiation protocols differed between centers. 
One hundred and fourteen (35%) patients received single 
dose (SD) irradiation and 208 (65%) patients were treated 
with various schemes o f  fractionated (F) TBI.
Prophylaxis o f  G V H D
Media» age in years (range) 34 (1-58)
Nos of patients 366
Male 211
Female 155
Disease status transplant
First chronic phase 238
Accelerated phase 79
2nd or subsequent chronic phase 21
Blast transformation 16
Status not given 12
Median interval from diagnosis to BMT in days 827
(range) (70-3719)
No. transplanted <1 year from diagnosis 37
No. transplanted 1-2 years from diagnosis 117
No. transplanted 2-3 years from diagnosis 78
No. transplanted > 3  years from diagnosis 123
Not given 11
Donor/recipient sex match (absolute Nos)
MM 109
FM 99
MF 58
FF 80
Not given 20
Prophylaxis for GVHD (absolute Nos)
CsA and MTX 202
In vivo TCD (ATG ± antibody) 71
Ex vivo TCD 58
CsA alone 19
Other/not given 16
Total body irradiation (absolute Nos)
Single dose 114
Fractionated 208
Occurrence of acute GVHD
Grade 0 107
Grade I 81
Grade II 71
Grade III 58
Grade IV 49
Donor ancl recipient com patib ility
All donor/recipient (D/R) pairs were HLA-A, -B and -DR 
matched using serological methods. The class II loci were 
typed either by serological methods or by more definitive 
DNA-based methods. The latter, ie RFLP, PCR sequence- 
specific oligonucleotide probing (PCR-SSOP) and PCR 
sequence-specific priming (PCR-SSP), have varying pow­
ers of resolution o f  class II specificities.16 Recently these 
methods have been used to improve donor selection. In 
order to analyze the impact o f  more accurate HLA class II 
typing on the clinical outcom e o f  transplant, we required 
additional information on the nature and results of the 
matching techniques em ployed for individual patients. We 
sent a further detailed questionnaire to all BMT centers
There was considerable variation between centers in the concerned. Forty-seven centers replied, giving complete
measures used to prevent GVHD. Two hundred and two 
(55%) patients received C sA  and short course MTX.15
data on 300 D/R pairs, who are evaluable for survival, LFS, 
TRM and RI. HLA-DRB 1 -specific alleles were identical for
Fifty-eight (16%) received  marrow which had been 210 D/R pairs. There were one or two HLA-DRB 1 mis-
depleted of T cells ex vivo (ex vivo  TCD). An additional matches for 31 D/R pairs and specific HLA-DRB 1 typing
71 (19%) patients received in vivo T cell depletion (in vivo had not been done in 59. HLA-DQB1 alleles were identical
TCD) with either m onoclonal antibodies or anti-thymocyte for 164 D/R pairs, mismatched for 14 and not done in 122
globulin (ATG). N ineteen (5%) patients were treated with pairs. HLA-DPB1 alleles were identical for 36 D/R pairs,
CsA alone and information relating to the method of mismatched for 81, and not performed in 183 donors and
GVHD prophylaxis was unavailable for 16 patients. their recipients.
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We have identified three different groups of patients, donor gender, gender matching, TBI method, disease stage
according to the HLA-DRB 1 D/R compatibility (Table 2). at time of transplant, time interval between diagnosis and
Two hundred and ten patients who received marrow from BMT, method of prophylaxis of GVHD, incidence and
an HLA-A, -B and DRB1 identical donor were referred to grade of acute GVHD and graft failure and rejection.
1 (matched group). Thirty-one patients who 
bone marrow from a donor who was HLA-DRB 1
In a second analysis, a sub-group of 300 patients for 
whom information was available concerning specific HLA-
mismutched were referred to as group 2 (mismatched DRB1 typing was divided into three groups, ie matched,
group). Fifty-nine patients in whom specific HLA-DRB I mismatched and not known. Patient-, disease- and
typing was not performed were referred to as group 3. treatment-related variables were compared between the
were no differences between the three groups of three cohorts using the x 2 statistical method for qualitative
patients with respect to age, interval from diagnosis to variables. All variables recognized as possible prognostic
transplant, and the method of TBI. However, a higher pro- factors or differing significantly between the three groups
patients in group 1 were transplanted in first in univariate analysis were studied using the proportional
chronic phase than in group 2 (P = 0.03) and in group 3 hazard model.19 In addition to HLA-DRB 1 typing, we stud-
(P = 0.024). There was no difference between groups 1 and ied patient age at transplant, patient gender, donor gender,
2 with respect to the prophylaxis of GVHD. In contrast, year of transplant, disease status at time of transplant (first
patients in group 3 were more likely to receive in vitro or chronic phase vj all other stages), time interval between
in vivo T  cell-depleted marrow than in group 1 (P = 0.02). diagnosis and transplant, method of prophylaxis of GVHD 
(CsA and MTX vs in vivo or ex vivo TCD) and TBI 
(fractionated vs single dose).
Results
All patients
Statistical analysis
»
All analyses were performed using the BMDP statistical 
package. Leukemia-free survival (LFS) was defined as sur­
vival without evidence of hematological relapse. To evalu­
ate the probability of relapse (RI), patients dying either 
from the toxicity of the procedure or from any other cause 
not related to leukemia were censored at the time of death.
The transplant-related mortality (TRM) was defined as Engraftment: Engraftment was defined as the attainment of
death while in complete remission and patients were cen- a peripheral blood ANC >  0.5 x 109/1 for 3 consecutive
sored at time of relapse or last follow-up. LFS, RI, TRM days. Three hundred and thirteen patients were evaluable
and overall survival were estimated by the product-Iimit for engraftment. Two hundred and seventy-nine (89%)
,17 patients engrafted and 34 (11%) patients experienced
In the entire population of patients who received an UD graft rejection.
{n = 366), a series of characteristics were studied for
a on outcome the rank test Survival leukemia-free survival: O f 366 evaluable
(Mantel~Cox),,K ie patient age at transplant, patient patients, 230 have died. The overall survival was 37 ±3%
13
Table 2 Characteristics of ihe ihree groups
Patient numbers
Median follow-up in months (range) 
Median age in years (range)
Interval diagnosis to BMT in days (n 
Disease status at transplant 
I'irst chronic phase 
Advanced phase 
Not known 
Total body irradiation
Single dose 
Fractionated
N o T
Prophylaxis against GVHD 
CsÂ
CsA and MTX
In vivo TCI)
In vitro TCI)
Group I 
DRB!  m atched
210
29.5
34
816
153
54
3
63
128
19
I I
124
26
45
4
(2-'
( I - 5 9 )  
(70-3719)
Group 2 
D RB I m ismatched
31
47
31
887
17
14“
1 0
18
3
2
22
5
(1-89)
(15-47)
(354-3494)
Group 3 
DRB1 not done
59
55
35
846
34
24"
21
34
4
4
24
I4 C
16
1
(22- 110)
(11-58) 
(216-8573)
“Group 1 r.v group 2: / ’ = 0.03. 
"Group 2 r.v group 3: / ’ = 0.024. 
•'Group I r.v group 3: P = 0.02.
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at 2 years and 35 ± 3% at 5 years. Three factors were ident- at 5 years. In univariate analysis, four factors had signifi-
in univariate analysis which cant on the risk of relapse: status at transplant
actuarial survival (Table 3): disease status at transplant (12 ± 3% for patients transplanted in first chronic phase and
(44 ±  3% (first chronic phase) vs 23 ± 4% (advanced phase) 29 ±  5% for with more advanced
(P = 0.0002); time interval from diagnosis to BMT (P = 0.009)); the method of prophylaxis o f GVHD (5 ± 2%,
(40 ± 4% for patients transplanted before the median of 827 29 ± 9% and 36 ± 8% respectively (P <  0.0001 )); the grade
days from diagnosis and 33 ±4%  for those transplanted of acute GVHD (20 ±4% , 14 ±5% , and 5 + 4% respect-
beyond 827 days from diagnosis (P = 0.04)); and the grade ively (P = 0.02)); and the technique of administering TBI
of acute GVHD (respectively 49 ± 4% (grade 0-1), 41 ± 6% (8 ± 3% (SD) v,v 23 ±  4% (F) (P = 0.04)).
(grade II) and 13 ± 3% (grade III-IV) (P <  0.0001)).
The LFS was 33 ±2%  and 31 ±3%, 2 years and 5 years 
after transplant, respectively. Of the variables analyzed for
Influence o f  HLA-DRB I matching on outcome
their influence on LFS, four had a significant effect: disease Three hundred donor and recipient pairs were evaluable for
status at transplant (40 + 3% vs 20 ±4% (P = 0.0001)); the determination of the influence of HLA-DRB 1 matching
time interval from diagnosis to BMT (38 ± 4% compared to on outcome. Patients were defined as identically matched
28 ±  3% (P = 0.01)); the method of prophylaxis of GVHD (group 1) or mismatched (group 2) according to the criteria
(41 ±3%  (CsA and MTX), 28+5%  (in vivo TCD) and set out in theset out in the Methods section. Patients in wh m HLA- 
20 ±5%  (ex vivo TCD) respectively (P = 0.001)); and the DRB1 typing results were not known were defined as 
grade of acute GVHD (43 ±4% , 37 + 6% and 13 ±3%  group 3. 
respectively (P =  0.0009)).
Engraftment
Transplant-related mortality: Death due to transplant- of the 300 D/R pairs. Graft rejection occurred in 16 (8%)
related toxicity occurred in 210 patients, giving a 2 year of the 187 patients in group I, in three o f the 24 patients
probability of TRM of 61 ± 3%. Factors which significantly in group 2 (12.5%) and in 6 of the 47 (12.7%) in group
affected the risk of TRM in univariate analysis were: status 3 (P = NS). 
at transplant (55 ±3%  (in first chronic phase) vs 72 ±5%
(in advanced phase) (P = 0.002)); time interval from diag- Leukemia-free survival: HLA-DRB 1 matching is the most
nosis to BMT (56 ±4%  vs 65+4%  (P = 0.04)); and the important factor influencing LFS. The 210 patients in the
grade of acute GVHD (46 ±  4%, 57 ± 6% and 87 + 3% 
respectively (P <  0.0001)).
matched group (group 1 ) had an LFS at 2 years of 44 ± 3% 
compared to 17 + 7% for the 31 patients in the mismatched 
group (group 2) (P = 0.0004) and to 17 ±5%  for the 59 
Relapse incidence: Thirty-four patients had an hematolog- patients in group 3 (P <  0.0001) (Figure 1). The influence 
ical relapse, of whom 20 have subsequently died. The actu- of HLA-DQB1 and HLA-DPB1 were studied indepen- 
arial risk of relapse was 16 + 3% at 2 years and 20 + 3% dently in the HLA-DRB 1 matched group (group 1) and in
groups 2 and 3 (Table 4). The LFS did not appear to be
Table 3 Univariate analysis of 366 patients: 2 years leukemia-free sur­
vival, relapse incidence, survival and transplant-related mortality
Variables LFS % RI % Survival
%
TRM %
Interval diagnosis-BMT
<M edian of 827 days 38 ± 4 13 ± 3 40 ± 4 56 ± 4
>M edian of 827 days 28 ± 3 22 ± 5 33 ± 4 65 ± 4
P value 0.01 0.11 0.04 0.04
Total body irradiation
Single dose 36 ± 4 8 ± 3 3 6 ± 4 61 ± 5
Fractionated 30 ± 3 23 ± 4 37 ± 3 60 ± 4
P value 0.36 0.04 0.94 0.89
Disease status at BMT
First chronic phase 40 ± 3 12 ± 3 44 ± 3 55 ± 3
Advanced phase 20 ± 4 29 ± 5 23 ± 4 72 ± 5
P value 0.0001 0.009 0.0002 0.002
GVHD prophylaxis
CsA. and MTX 41 ± 3 5 ± 2 41 ± 3 57 ± 3
In vivo TCD 28 ± 5 36 ± 8 38 ± 6 56 ± 6
Ex vivo TCD 20 ± 5 29 ± 9 29 ± 6 72 ± 7
P value 0.001 <0.0001 0.1 0.06
Grade of GVHD
0-1 (n= 188) 43 ± 4 20 + 4 49 ± 4 46 ± 4
II (n = 71 ) 37 ± 6 14 + 5 41 ± 6 57 + 6
III-IV  (n = 107) 13 ± 3 5 ± 4 13 ± 3 87 ± 3
P value 0.0009 0.02 <0.0001 <0.0001
significantly affected by the HLA-DQ or -DP disparity. 
However, the influence of HLA-DQB 1 or -DPB1 cannot 
be adequately assessed due to the small number of patients 
for whom adequate data are available.
1
0.8 -
0.6
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0
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Group 3
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2
T
4
P< 0.0001
T
6
T8
Years
Significant P values are indicated in bold font,
Figure 1 Kaplan-Meier probability of leukemia-free survival in patients 
who received DRB 1-matched transplants (group I) compared with those 
who received DRB 1-mismatched transplants (group 2) and with those for 
whom HLA-DRB 1 typing was not done (group 3). The probability of 
leukemia-free survival at 2 years was 44 ± 3 %  for 210 DRB 1-matched 
transplants, 17 ± 7 %  for 31 mismatched transplants and 17 ± 5 %  when 
DRB I typing was not done (P <  0.0001).
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'Table 4 HLA class II compatibility. Impact on 2 years LFS
Group 1 ( DBI id) Group II (DRBI MM) Group Ul (DRBI ND) Total
n LFS% n LFS%
r  ■ ■ -* * ‘ W —" 1 ^ i i —1 . ni l  * W *^ ™  —r• —i i i 0  i •— I 1 .Su.k.|i» ■■ . «f.
il LFS% n
210 44 ± 3 31 17 ± 7 59 17 ± 5 “ 300
PQ B1
Identical (id) 135 51 ± 4 15 20 ± 10 14 7 ± 7 164
Mismatched (MM) 6 50 ± 20 7 28 ± 17 1 0 14
Not done (ND) 69 47 ± 6 9 25 ± 15 44 20 ± 6 i ni ém
P = 0.85 P = 0.98 P = 0,25
PPB1
Identical (id) 31 53 ± 9 4 0 1 0 36
Mismatched (MM) 68 50 ± 6 12 33 ± 14 1 0 81
Not done (ND) 111 44 ± 5 15 21 ± 11 57 23 ± 6 183
P =  0.13 P =  0.25 P = 0.65
G ro u p  1 r.v group 2: P = 0.0004; group 1 v.y group 3: P -  0.0001,
The matched and mismatched groups were also studied 
•for the influence of other prognostic factors. Two hundred 
and four evaluable patients were transplanted in first 
chronic phase, 153 in group 1, 17 in group 2 and 34 in 
group 3. The LFS was improved if the donor was HLA- 
D R B  1 matched, being 47 ± 4% in group 1 compared to
2 3  ± 10% in group 2 (P = 0.014). This was largely due to 
a  reduced TRM of 48 ±  4% for patients in group 1 com­
pared to 71 ± 11% in group 2 (P = 0.013). The LFS was
2 9  ± 8% for the 34 patients in group 3, and the difference 
w ith group 1 was also statistically significant (P = 0.05), 
w ith a TRM of 66 ± 9%. Similar differences between the 
three groups were seen for patients who were transplanted 
in  advanced phases o f the disease.
; HLA-DRB 1 matching was 
ilso the most important factor influencing the risk of TRM
(Figure 2). The TRM was 49 ± 4%  in group 1 (matched
and 79 ± 8% in group 2 (mismatched group)
0.0002). This was largely related to an increased inci-
1
0.8 -
0.6 -
0.4
0.2 -
0
... .*■,.......................
Group 3
Group 2
Group 1
P= 0.0002
0 2 4
Years
6
i
8
Figure 2 Transplant-related mortality in patients who received matched 
transplants (group I) compared to those who received mismatched trails- 
plants (group 2) and to those for whom HLA-DRB 1 typing was not done 
(group 3). At 2 years after transplantation, the transplant-related mortality 
was 49 ±4%  for the 210 DRB I-matched patients, and respectively 
7 C) ± 8% and 80 ± 6% for 31 HLA-DRB I-mismatched transplants or when 
HLA-DRB 1 typing was not done (P = 0.0002),
dence o f acute GVHD of grade II—IV in the mismatched
group (23 of 31 patients) (74%) compared to the matched 
group (93 of 210 patients) (44%) (P = 0.002). The TRM 
was also higher for the patients of group 3 (80 + 6%) when 
compared to group 1 (P <  0.0001). Grade II—IV acute 
GVHD occurred in 32 of the 59 patients (54%) (NS).
Relapse incidence: The relapse incidence was not affected
by HLA-DRB an ty.
Multivariate analysis: Sufficient data were available for 
286 patients to be analyzed in a Cox proportional hazard 
mode]14 using the covariates described in the Methods sec­
tion. The results are shown in Table 5. Three factors were 
associated with LFS and relapse risk: there was a significant
reduction in relapse risk with an improved LFS for patients
transplanted in the first chronic phase of the disease, who
were SD TBI, and received x n d
MTX as prophylaxis against GVHD. Two factors were
associated improved survival TRM:
younger age when age was analyzed as a continuous vari­
able, and HLA compatibility. Indeed, HLA-DRB I
Table 5 Results of multivariate analysis for 286 patients
Unfa i 'amble prognostic Relative risk P valut
factor
Survival Older age
LFS
Advanced phase di* 
DRB I mismatched 
I not done 
Advanced phase dis 
ln vivo/ex vivo TC
RI
DRB I mismatched 
DRB1 not done 
Fractionated TBI 
Advanced phase dise 
In vivo/ex vivo TCD 
Fractionated TBI
TRM r tt*
DRB1 mismatched 
DRB 1 not done 
Advanced phase
1.02 (1.01-1.04) 
1.59 (1,15-2.22)
2.07 ( 1.26-3.38) 
1.89 (1.29-2.78)
1.69 (1,23-2.3)
1.48 ( 1.07-2.
1.85 (1.14-3.02) 
1.77 (1.22-2.58)
1.4 (1.02-1.
5.5 (2.27-14.3) 
10.6 (3.64-30.8) 
7.45 (2.35-23.6) 
1,02 (1.005..1.04)
2.07 (1.25-3.44) 
1.87 (1.24-2.8) 
1.47 (1.03-2.08)
0.0052 
0.005 
0.004 
0 . 0 0 12  
0 . 0 12  
0 .0 1 7
0 . 0 13 
0.0028 
0.04 
0 . 0 0 0 1
<0.000 i
0.0006
0 . 0 1 2
0.0049
0.002
0.03
-•#§ Ä  
4M «
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16 ing was the most significant factor influencing survival her of variables which may be used to improve patient and
(P = 0.004), LFS (P = 0.013) and TRM (P = 0.0049). The
outcome for patients without HLA-DRB 1 typing res 
was comparable to that for patients with an HLA-DRB 1
donor selection.
We have demonstrated that the most influential factor 
for survival, leukemia-free survival and transplant-related
mismatched donor and there was a significant difference mortality is the presence of HLA disparity. This in turn is 
when compared to HLA-DRB 1 matched transplants for associated with an increased risk of severe acute GVHD.
survival (P = 0.0012), LFS (P = 0.0028) and TRM 
(P = 0.0026).
From the results of the multivariate analysis we have
The selection of donors who are more precisely matched 
with their recipients is essential if we are to be able to 
reduce the incidence o f GVHD-related mortality and mor-
have not previously been 
DNA-based typing methods for HLA-DRB 1 are now avail
at this
defined a ‘good risk’ group, ie patients transplanted in first bidity. Due to the extreme polymorphism of certain HLA 
chronic phase from a matched donor and treated with CsA loci and limited resolution of serological typing, such mis- 
and MTX as prophylaxis against GVHD. The survival, matches exposed. However, 
LFS, TRM and RI for this group are 51 ±5% , 51 ±5%
(Figure 3), 47 ± 5% and 2 ±2%  respectively. In contrast, able16 and we have clearly shown that ide 
the TRM for patients transplanted for advanced disease as defined by molecular methods strongly correlates with 
from an HLA-mismatched donor is 94%. improved outcome compared with either serological DR
matching only or HLA-DRB 1 mismatching. This suggests 
that these mismatches are immunogenic to allo-specific 
HLA-DRB 1 restricted T cells.
Despite the obvious advantages that HLA-DRB 1 match- 
HLA-identical sibling donors can be found for approxi- ing seems to offer, the actual benefits may have been under- 
mately 30-40% of patients with chronic myeloid leukemia. estimated in this study. This is because the exact definition 
Over the last decade, the development of numerous regis- of the alleles present may only be achieved by sequencing, 
tries has facilitated the identification of HLA-A, -B and DNA-based techniques to identify HLA-DRB 1 alleles have
Discussion
-DR identical volunteer unrelated donors for an additional been developed only within the last decade and have under- 
25-45% of patients.20,21 However, despite a successful out- gone modifications and improvements for the relatively low 
come for some patients, UD BMT is associated with a resolution RFLP to higher resolution PCR-SSOP and PCR- 
higher incidence of complications, specifically primary or SSP. Furthermore, these latter techniques are dependent on 
secondary graft failure, severe acute GVHD, and viral knowledge o f the sequence to optimize probe and primer
design. These too have been improving as sequence infor-infections, than HLA-identical sibling transplant.
together with recent publications confirming improved sur- mation available. It is likely that a
vival times with a-interferon and possibly with autologous higher proportion of HLA-DRB 1 ‘matched’ pairs are truly
transplantation,6“8 has made the role of UD BMT in CML
increasingly to define. of the earlier.
in patients typed recently than in those typed
recipient and donor, and/or improved transplant technique The impact of HLA-DQB I matching on the outcome of
may reduce the incidence of post-BMT complications and UD BMT cannot be assessed accurately as so lew •s
result in improved clinical outcome. In this study, we have matched at HLA-DRB 1 were mismatched at HLA-DQB 1.
retrospectively analyzed the impact of prognostic factors Due to the proximity of the loci (100 kb)-5 and a lack of
on the outcome of UD BMT in a large cohort of patients ation strong associations have
transplanted for CML in Europe, and have identified a num- developed between HLA-DRB I and HLA-DQB I. In prac­
tice, matching for HLA-DRB 1 means matching for HLA-
DQB 1. Similarly mismatc for HLA-DRB 1 are
likely to be mismatched for HLA-DQB 1.
Linkage between HLA-DRB 1 and HLA-DPB1 is not evi­
dent. A high level of recombination occurs 
loci20 and as a r 
A, -B i
most unrelated pairs matched at HLA-
I are mismatched at HLA- 1 . .27,JH I_
ever, mismatching at HLA-DPB 1 did not seem to signifi­
cantly affect transplant outcome in HLA-DRB I mate
pairs as has been previously reported.
The role of class I mismatching cannot be estimated from 
this study as all the evaluable patients were class I matched 
by serological methods. It is probable that some degree of 
class I mismatching would have been apparent if in all D/R 
pairs the testing had included isoelectric focusing (IEF). A
Years
Figure 3 Kaplan-Meier probability of survival for ‘good-risk’ patients. 
At 2 years after transplantation, the probability of survival was 517< for 
99 patients transplanted in first chronic phase from a matched donor and 
treated with CsA and MTX as prophylaxis against GVHD.
ration addressing the role of assays for c 
toxic T cell precursors (CTLp) in the selection of donors 
for UD BMT reported an association of high fr
CTLp and class I mismatching as determined by IEF.-10
Several variables which are known to influence the out­
come of HLA-identical sibling transplants were also found
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to have a prognostic role of UD BMT. Older age was an 
unfavorable risk factor for survival and transplant-related 
mortality. Several studies have found a significant effect 
for recipient age.4-24-31 More recent studies have suggested 
that the adverse effect of patient age may be largely related 
to HLA compatibility. In a series of 33 patients aged 50 
years or older, who received transplants from HLA-ident­
ical family members for CML in chronic phase within 1 
year of diagnosis, the probability of survival at 4 years was 
in excess of 80%.32 In contrast, in a group of patients aged 
less than 18 years who underwent UD BMT for acute and 
chronic leukemias, there was no significant difference in 
the LFS between patients who were serologically matched 
with their donors and those who were mismatched.33
Patients transplanted for advanced disease had signifi­
cantly decreased survival, LFS and increased RI. This too 
confirms previously reported results for both sibling and 
unrelated donor transplants.4,24-31 Early transplant, ie prior 
to the median duration between diagnosis and BMT, con­
ferred a benefit for survival, LFS and TRM in univariate, 
and RI in multivariate analysis. It is possible that there is 
a delay in proceeding to UD BMT compared to sibling 
transplant, partly because of the time restraints imposed by 
the need to identify a donor34 and partly because of a natu­
ral reluctance on the part of patient and/or physician to 
undertake a high-risk procedure. This delay may contribute 
to disease progression which itself has an adverse effect on 
transplant outcome. Major cytogenetic responses to a-IFN 
are rarely seen within 9-12 months of initiation of therapy5 
and patients are understandably advised to persist with a- 
IFN for prolonged periods of time before considering UD 
BMT. However, a multivariate analysis of patients 
undergoing allogeneic transplants for CML has recently 
demonstrated an adverse effect of prolonged (ie > 12  
months) treatment with a-IFN. This effect was mainly 
attributable to an increased risk of graft failure and fatal 
infections. In this study, primary or secondary graft failure 
occurred exclusively in patients with donors other than 
HLA-identical family members and was further restricted 
to patients who had been previously exposed to a-IFN.35 
This observation requires confirmation but if correct adds 
further complexity to decisions relating to the optimal 
management of CML.
Of the 286 patients who received TBI as part of their 
conditioning regimen and were evaluable in multivariate 
analysis, one-third received SD TBI and two-thirds were 
treated with fractionated TBI. Fractionated TBI has an 
adverse influence on the relapse rate. This observation con­
firms that of a retrospective study from the French Registry 
which reported a significant increase in relapse incidence 
for patients treated with fractionated TBI compared to those 
who received SD TBI36 but is in contrast to a number of 
previously published studies. In a review of the literature 
pertaining to TBI techniques for both acute and chronic 
leukemias, identical relapse rates were found for SD and 
fractionated TBI in patients who received T cell non­
depleted bone marrow.37 Similarly a report from the Inter­
national Bone Marrow Transplant Registry did not identify 
fractionated TBI as a risk factor for relapse after allogeneic 
transplant for CML.31 It is likely that the differences 
between these reports reflect the variables associated with
irradiation (ie number of fractions, total dose, dose rate, 
radiation source, use of shielding etc) and will only be 
resolved when the radiobiological effects of these para­
meters can be accurately predicted.
The method of GVHD prophylaxis influenced both 
leukemia-free survival and relapse risk. The increased inci­
dence of acute GVHD has encouraged many investigators 
to employ ex vivo or in vivo T cell depletion in order to 
reduce the associated morbidity and mortality. In this analy­
sis, it has not been possible to investigate the effects of 
different methods of ex vivo and in vivo T cell depletion, 
due to the small number of patients in each category, but 
it is entirely possible that the methodology itself may affect 
outcome. In HLA-identical sibling marrow transplants for 
CML, T cell depletion has been associated with a reduction 
in the incidence and severity of GVHD but at the expense 
of a higher frequency of graft failure and leukemic 
relapse.38 In a series of 462 patients (of whom 196 had 
CML), who received UD BMT facilitated by the National 
Marrow Donor Panel (NMDP), 70 received T cell-depleted 
grafts. They did not appear to have an increased risk of 
relapse when compared to patients who received unmanipu­
lated marrow.34 Similarly, in a series of 48 consecutive 
patients who received T cell-depleted unrelated marrow at 
a single center, the 2 year probability of relapse was low at 
8.8%, suggesting an apparent preservation of graft-versus- 
leukemia activity.39 However, in our large retrospective 
study, we have found that T cell depletion was an inde­
pendent risk factor for relapse and was also associated with 
a decreased LFS in both univariate and multivariate analy­
sis. It is now possible to overcome some of the deleterious 
effects of T cell depletion in the sibling transplant setting 
by the use of donor leukocyte infusions at the time of 
relapse 40,41 In the future it may be appropriate to exploit 
the beneficial effects of T cell depletion (ie a reduced inci­
dence and severity of acute and chronic GVHD) by admin­
istering T cell-depleted marrow and then replacing limited 
numbers of lymphocytes at various time points post­
transplant.42
In summary we have identified a number of prognostic 
variables for UD BMT for CML. Some of these (ie age, 
disease status and interval from diagnosis to transplant) 
were expected. We have also shown the adverse effect of 
T cell depletion as it was performed during the years of 
this study. More importantly we have demonstrated the 
importance of accurate HLA-DRB 1 matching on the out­
come of transplant. Other parameters, in particular the 
CMV serostatus of the donor and recipient, HLA-C match­
ing43,44 and functional studies such as CTLp assays30 could 
not be analyzed in this particular study but are likely to play 
a role in determining transplant outcome. In the meantime, 
accurate DNA-based methodology for HLA-DRB 1 match­
ing is now available and should be used to facilitate the 
identification of the optimal donor. Our data suggest that 
the long-term outcome of patients with CML with favorable 
prognostic features can approach that of patients trans­
planted from HLA-identical siblings. In contrast, the 
transplant-related mortality of patients transplanted in 
advanced phases of the disease from non-HLA-DRBl- 
identical donors is such that alternative therapies should be 
found for these individuals.
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Appendix
The following transplantation centers participated in the University Hospital, Leiden, The Netherlands; Institut of
CLWP registry of the EBMT; Hôpital Saint Louis, Paris, Hematology Seragnoli, Bologna, Italy; Hôpital Henri
France; Hammersmith Hospital, London, UK; Rigshospita- Mondor, Creteil, France; Hôpital Michallon, Grenoble,
let, Copenhagen, Denmark; Hospital Clinic, Barcelona, France; Hôpital Cimiez, Nice, France; Hotel-Dieu, Nantes,
Spain; Royal Free Hospital, London, UK; Hôpital Claude France; University Hospital Utrecht, The Netherlands;
Hurez, Lille, France; Klinikum Großhadern, München, Glasgow Royal Infirmary, Glasgow, UK; Hôpital de Bra-
Germany; Abt. Innere M edizinlll, Ulm, Germany; Osped- bois, Nancy, France; Hôpital Cantonnai
ale San Martino, Genova, Italy; Rikshospitalet, Oslo, Nor- Geneva, Switzerland; Ospedale di Niguarda, Milano, Italy;
way; Huddinge Hospital, Huddinge, Sweden; University Policlinico San Matteo, Pavia, Italy; Addenbrookes Hospi-
Hospital St Radboud, Nijmegen, The Netherlands; Hôpital tal, Cambridge, UK; Hôpital Jean Minjoz,
du Haut Leveque, Pessac, France; Hadassah University France; Hôpital Necker, Paris, France; Ospedale di Carregi,
Hospital, Jerusalem, Israel; Royal Liverpool University Firenze, Italy; Heinrich Heine Universität, Düsseldorf, Ger-
Hospital, Liverpool, UK; University Hospital, Leuven, many; Hôpital de Enfants Malades, Paris, France; CHRU,
Belgium; Medical School o f  Hannover, Hannover, Ger- Angers, France; Royal Infirmary, Edinburgh, UK; CHRU,
many; Hôpital Edouard Herriot, Lyon, France; Kantonspi- Saint Etienne, France; Ospedale Regina Margherita, Tor-
tal, Basel, Switzerland; Cliniques universitaires St Luc ino, Italy; Charing Cross Hospital, London, UK; Institut
Brussels, Belgium; University Hospital, Innsbruck, Austria; Gustave Roussy, Villejuif, France.
